WEST PHARMACEUTICAL SERVICES, INC. Comprehensive Income
WEST PHARMACEUTICAL SERVICES, INC. (WST) reported Comprehensive Income of $138.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-07-23
- WEST PHARMACEUTICAL SERVICES, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was $138.80M, a 44.17% decline year-over-year.
- WEST PHARMACEUTICAL SERVICES, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was $119.10M, a 16.36% decline year-over-year.
- WEST PHARMACEUTICAL SERVICES, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was $128.90M, a 1453.01% increase year-over-year.
- WEST PHARMACEUTICAL SERVICES, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was $126.40M, a 41.64% decline year-over-year.
- WEST PHARMACEUTICAL SERVICES, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was $646.30M, a 70.80% increase from fiscal 2024.
- WEST PHARMACEUTICAL SERVICES, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was $378.40M, a 40.18% decline from fiscal 2023.
- WEST PHARMACEUTICAL SERVICES, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was $632.60M, a 12.46% increase from fiscal 2022.
- WEST PHARMACEUTICAL SERVICES, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was $562.50M, a 8.21% decline from fiscal 2021.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | $138.80M 10-Q · filed 2026-07-23 | $257.90M 10-Q · filed 2026-07-23 | $386.80M derived: sum of 3 quarters · filed 2026-07-23 | $513.20M derived: sum of 4 quarters · filed 2026-07-23 |
| 2026-03-31 | $119.10M 10-Q · filed 2026-04-23 | $248.00M derived: sum of 2 quarters · filed 2026-04-23 | $374.40M derived: sum of 3 quarters · filed 2026-04-23 | $623.00M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-12-31 | $128.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $255.30M derived: sum of 2 quarters · filed 2026-02-17 | $503.90M derived: sum of 3 quarters · filed 2026-07-23 | $646.30M 10-K · filed 2026-02-17 |
| 2025-09-30 | $126.40M 10-Q · filed 2025-10-23 | $375.00M derived: sum of 2 quarters · filed 2026-07-23 | $517.40M 10-Q · filed 2025-10-23 | $525.70M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-06-30 | $248.60M 10-Q · filed 2026-07-23 | $391.00M 10-Q · filed 2026-07-23 | $399.30M derived: sum of 3 quarters · filed 2026-07-23 | $615.90M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-03-31 | $142.40M 10-Q · filed 2026-04-23 | $150.70M derived: sum of 2 quarters · filed 2026-04-23 | $367.30M derived: sum of 3 quarters · filed 2026-04-23 | $454.00M derived: sum of 4 quarters · filed 2026-04-23 |
| 2024-12-31 | $8.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $224.90M derived: sum of 2 quarters · filed 2026-02-17 | $311.60M derived: sum of 3 quarters · filed 2026-02-17 | $378.40M 10-K · filed 2026-02-17 |
| 2024-09-30 | $216.60M 10-Q · filed 2025-10-23 | $303.30M derived: sum of 2 quarters · filed 2025-10-23 | $370.10M 10-Q · filed 2025-10-23 | $586.30M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $86.70M 10-Q · filed 2025-07-24 | $153.50M 10-Q · filed 2025-07-24 | $369.70M derived: sum of 3 quarters · filed 2026-02-17 | $491.50M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $66.80M 10-Q · filed 2025-04-24 | $283.00M derived: sum of 2 quarters · filed 2026-02-17 | $404.80M derived: sum of 3 quarters · filed 2026-02-17 | $544.80M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $216.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $338.00M derived: sum of 2 quarters · filed 2026-02-17 | $478.00M derived: sum of 3 quarters · filed 2026-02-17 | $632.60M 10-K · filed 2026-02-17 |
| 2023-09-30 | $121.80M 10-Q · filed 2024-10-24 | $261.80M derived: sum of 2 quarters · filed 2024-10-24 | $416.40M 10-Q · filed 2024-10-24 | $644.90M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | $140.00M 10-Q · filed 2024-07-25 | $294.60M 10-Q · filed 2024-07-25 | $523.10M derived: sum of 3 quarters · filed 2025-02-18 | $581.10M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | $154.60M 10-Q · filed 2024-04-25 | $383.10M derived: sum of 2 quarters · filed 2025-02-18 | $441.10M derived: sum of 3 quarters · filed 2025-02-18 | $566.10M derived: sum of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | $228.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $286.50M derived: sum of 2 quarters · filed 2025-02-18 | $411.50M derived: sum of 3 quarters · filed 2025-02-18 | $562.50M 10-K · filed 2025-02-18 |
| 2022-09-30 | $58.00M 10-Q · filed 2023-10-26 | $183.00M derived: sum of 2 quarters · filed 2023-10-26 | $334.00M 10-Q · filed 2023-10-26 | $477.80M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $125.00M 10-Q · filed 2023-07-27 | $276.00M 10-Q · filed 2023-07-27 | $419.80M derived: sum of 3 quarters · filed 2024-02-20 | $572.90M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $151.00M 10-Q · filed 2023-04-27 | $294.80M derived: sum of 2 quarters · filed 2024-02-20 | $447.90M derived: sum of 3 quarters · filed 2024-02-20 | $642.20M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $143.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $296.90M derived: sum of 2 quarters · filed 2024-02-20 | $491.20M derived: sum of 3 quarters · filed 2024-02-20 | $612.80M 10-K · filed 2024-02-20 |
| 2021-09-30 | $153.10M 10-Q · filed 2022-10-27 | $347.40M derived: sum of 2 quarters · filed 2022-10-27 | $469.00M 10-Q · filed 2022-10-27 | $616.30M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $194.30M 10-Q · filed 2022-07-28 | $315.90M 10-Q · filed 2022-07-28 | $463.20M derived: sum of 3 quarters · filed 2023-02-21 | $573.80M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $121.60M 10-Q · filed 2022-04-28 | $268.90M derived: sum of 2 quarters · filed 2023-02-21 | $379.50M derived: sum of 3 quarters · filed 2023-02-21 | $475.20M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $147.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $257.90M derived: sum of 2 quarters · filed 2023-02-21 | $353.60M derived: sum of 3 quarters · filed 2023-02-21 | $385.20M 10-K · filed 2023-02-21 |
| 2020-09-30 | $110.60M 10-Q · filed 2021-10-28 | $206.30M derived: sum of 2 quarters · filed 2021-10-28 | $237.90M 10-Q · filed 2021-10-28 | $322.60M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | $95.70M 10-Q · filed 2021-07-30 | $127.30M 10-Q · filed 2021-07-30 | $212.00M derived: sum of 3 quarters · filed 2022-02-22 | $250.10M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | $31.60M 10-Q · filed 2021-04-30 | $116.30M derived: sum of 2 quarters · filed 2022-02-22 | $154.40M derived: sum of 3 quarters · filed 2022-02-22 | $221.70M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | $84.70M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $122.80M derived: sum of 2 quarters · filed 2022-02-22 | $190.10M derived: sum of 3 quarters · filed 2022-02-22 | $246.30M 10-K · filed 2022-02-22 |
| 2019-09-30 | $38.10M 10-Q · filed 2020-10-23 | $105.40M derived: sum of 2 quarters · filed 2020-10-23 | $161.60M 10-Q · filed 2020-10-23 | |
| 2019-06-30 | $67.30M 10-Q · filed 2020-07-24 | $123.50M 10-Q · filed 2020-07-24 | ||
| 2018-12-31 | $170.00M 10-K · filed 2021-02-23 | |||
| 2010-12-31 | $53.70M 10-K · filed 2011-02-28 | |||
| 2009-12-31 | $97.80M 10-K · filed 2011-02-28 | |||
| 2008-12-31 | $7.50M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |